论文部分内容阅读
10例肿瘤患者接受了胎儿淋巴因子激活的杀伤细胞(LAK)/基因重组白细胞介素—2(rIL—2)免疫过继疗法。除3名病人外,在免疫过继疗法之前均接受过手术治疗。在治疗过程中,除一名有轻微低热外,其它病人未出现任何毒副作用。一名患者在治疗过程中死亡。随访结果表明,已出院病人病情未见进展,其中一例病人已存活近3年。
Ten patients with tumors received fetal lymphokine-activated killer (LAK)/recombinant interleukin-2 (rIL-2) immunotherapy. All but three patients received surgical treatment prior to adoptive immunotherapy. In the course of treatment, except one with slight fever, other patients did not have any toxic side effects. One patient died during treatment. Follow-up results showed that no progress had been made in the condition of discharged patients, and one patient had survived for nearly 3 years.